articleAnnals of OncologyApr 22, 2019Closed access

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

ABAlexa B. SchrockCOChing OuyangJSJaideep SandhuESEthan S. SokolDXDexter X. Jin

Foundation Medicine (United States) · City Of Hope National Medical Center · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

625
total citations
FWCI
39.42
Percentile
100%
References
29
Citations per year

Authors

16

Topics & keywords

Topics
Keywords
  • Medicine
  • Nivolumab
  • Microsatellite instability
  • Pembrolizumab
  • Colorectal cancer
  • Oncology
  • Immune checkpoint
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.